Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm. Tagraxofusp is a fusion protein consisting of interleukin 3 fused to diphtheria toxin. From Wikipedia
Frontline patients in the CADENZA trial saw a median overall survival of 16.6 months with peripheral edema as the primary manageable side effect.
